A multicentre randomised double-blind placebo-controlled trial of zoledronic acid for knee osteoarthritis - the zap2 trial

Aitken, Dawn; Cai, Guoqi; Laslett, Laura L; Hill, CA; March, Lyn; Cicuttini, F.; Wluka, Anita E.; Wang, Y.; Antony, Benny; Blizzard, Leigh; Winzenberg, Tania; Martel‐Pelletier, Johanne; Pelletier, J.-P.; Jones, Graeme

doi:10.1016/j.joca.2020.02.121

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112 In a multicentre, randomised controlled trial involving knee OA patients with significant knee pain and MRIdetected BMLs (n = 223), 2 annual infusions with 5 mg of zoledronic acid (the most potent of all bisphosphonates) did not significantly reduce cartilage volume loss, knee pain or BML size although the study was designed for detecting effects on the bone-driven subgroup with BMLs which may likely have potential benefits from this therapy. 113 It was noted that more knee replacement procedures were performed in the zoledronic acid group compared with the placebo group (9% vs 2%) in contrast with other population-based studies. 114,115 Another study involving Osteoarthritis Initiative (OAI) female participants (n=346) showed that bisphosphonate therapy may be protective of radiographic knee OA progression in non-overweight patients with early-stage OA.…”

Section: Antiresorptive Drugs: Bisphosphonates and Denosumabmentioning

confidence: 89%

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

Oo¹,

Little²,

Duong³

et al. 2021

DDDT

113

163

View full text Add to dashboard Cite

Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved diseasemodifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.

show abstract

Section: Antiresorptive Drugs: Bisphosphonates and Denosumabmentioning

confidence: 89%

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

Oo¹,

Little²,

Duong³

et al. 2021

DDDT

113

163

View full text Add to dashboard Cite

show abstract

“…As for the treatment of osteoarthritis (OA), a study in rabbits with experimental knee osteoarthritis showed that ZA had protective effect on articular cartilage and subchondral bone (She et al, 2017). An initial trial showed that ZA may be effective in treating osteoarthritis (Aitken et al, 2018). However, we have not yet found strong evidence that osteoarthritis can benefit from ZA.…”

Section: Off-label Use With Higher Frequency In the Databasementioning

confidence: 99%

Novel methods and technologies for the evaluation of drug outcomes and policies

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

What is new in pharmacological treatment for osteoarthritis?

Gezer

Östör

2023

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

A multicentre randomised double-blind placebo-controlled trial of zoledronic acid for knee osteoarthritis - the zap2 trial

Cited by 3 publications

References 0 publications

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

Novel methods and technologies for the evaluation of drug outcomes and policies

What is new in pharmacological treatment for osteoarthritis?

Contact Info

Product

Resources

About